.png){kind=tracking}
The CEO of Pfizer, Albert Bourla, stated this Thursday that the field of oncology became the new objective of the American pharmaceutical company after the coronavirus pandemic: “Oncology is our new covid,” he indicated.
In an interview with The Claman Countdown program, Bourla also said that the company feels “very proud” of its actions to stop the coronavirus, a stage that “is behind us now.”
“We want to do [it] once more and I think oncology is our best chance to do it, but of course with many other therapeutic areas,” he added, while predicting that Pfizer will move “towards overall cancer survival.”
Bourla detailed that the company is “having a phenomenal portfolio performance” of drugs that use the patented technology for cancer treatment known as 'antibody-drug conjugate' (ADC), which was acquired by Pfizer at the time of purchasing the biotechnology company Seagen, for $43 billion. In December of that year, the purchase of the biotechnology company by the pharmaceutical company was finalised.
One of these medications is Padcev, which is mainly used to treat bladder cancer. According to Bourla, Padcev sales recorded a growth of 164% now that the oncology drug portfolio belongs to Pfizer.
“That demonstrates how well this money was invested,” he noted. According to the drug.com portal, the cost of a 20 milligram dose of Padcev is around $2,900.
Months ago, Pfizer's oncology director, Chris Boshoff, reported that the company is expected to have at least eight anti-cancer drugs by 2030.
Source: https://noticiasholisticas.com.ar/ceo-de-pfizer-albert-bourla-el-cancer-es-nuestro-nuevo-covid/
Nenhum comentário:
Postar um comentário